Skip to main content
. 2020 Apr 2;33(7):762–772. doi: 10.1111/tri.13601

Figure 2.

Figure 2

Duration of cyclosporine A (CsA) prophylaxis after myeloablative conditioning (MAC). (a) Duration of CsA prophylaxis regarding the relapse risk of malignant underlying disease (low relapse risk versus high relapse risk). (b) Duration of CsA prophylaxis regarding the underlying disease (malignant versus nonmalignant underlying disease). Responding centers (N = 74 of 75 participating centers).